TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03907111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan Gauze
Description: Gauze made by chitosan material

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: traditional gauze
Study: NCT03965754

Intervention type: BEHAVIORAL
Intervention: Social norms
Description: This intervention introduces recipients to descriptive social norms specifying that a majority of their colleagues have signed up for the program, which sets a normative standard against which recipients are expected to compare themselves and to change their behavior accordingly (i.e., when they realize that their behavior is discrepant from that of relevant others). The personal testimonial from a Geisinger medical director serves as a personal exemplar intended to further enhance the effect of the social norms with an implicit indication that the intended behavior is desirable and feasible.

Intervention type: BEHAVIORAL
Intervention: Loss framing
Description: This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction.

Intervention type: BEHAVIORAL
Intervention: Email reminder
Description: This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.

Intervention type: BEHAVIORAL
Intervention: Email reminder
Description: This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.

Intervention type: BEHAVIORAL
Intervention: Email reminder
Description: This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.
Study: NCT00883831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized manual acupuncture
Description: Acupuncture treatment will be provided according to traditional korean medicine (TKM) theory which focuses on patient's individual symptoms and conditions. 10-12 needles will be inserted into acupuncture point on the body except one arm where arteriovenous fistula is located for hemodialysis access. Needle retention time will be 30 minutes with intermittent manual stimulation to elicit de-qi sensation. Biweekly treatment will be conducted at non-dialysis access day or before hemodialysis at dialysis-access day for 6 weeks.
Study: NCT03556254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GGT
Description: In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGT
Description: In the absence of clarithromycin resistance, clarithromycin based sequential therapy will be given. In the presence of clarithromycin resistance but the absence of levofloxacin resistance, levofloxacin based sequential therapy will be given. In the presence of both clarithromycin and levofloxacin resistance or if culture fails, bismuth quadruple therapy will be given.
Study: NCT04860531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Facet Joints intra-articular injection with Platelet Rich Plasma
Description: Floroscopy guided by C-arm Intraarticular injection in Lumbar facet Joints

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Facet Joints intra-articular injection with a mixture of 0.5% lidocaine and 5mg/ml of betamethasone
Description: Lumbar Facet Joints intra-articular injection
Study: NCT01479777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Stepping (RT600 from Restorative Therapies, INC.)
Description: You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
Study: NCT00475839

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tension-free Vaginal Tape

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monarc sub-fascial hammock
Study: NCT03104465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: interactive. web-based mindfulness training complemented with mobile application
Study: NCT02455960

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01435876

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post exercise Surgery
Description: ORTHOPTICS/MINUS LENS THERAPY

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthoptics
Description: MINUS LENS THERAPY/ ORTHOPTICS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postop orthoptics
Description: ORTHOPTICS/MINUS LENS THERAPY

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post exercises surgery
Description: UNIOCULAR/BINOCULAR RECESSION/RESECTION
Study: NCT05413954

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group ate snacks composed of dried vegetables, one classical egg yolk and 2.3g of sunflower oil during 10 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test
Description: Tes group ate snacks composed of dried vegetables, one test egg yolk naturally enriched in rumenic acid, docosahexaenoic acid and punicic acid, 0.34g of pomegranate seed oil and 2.26g of olive oil during 10 weeks
Study: NCT01777503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: prasugrel 5 mg o.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75 mg o.d.
Study: NCT02254980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitamin-E diffused polyethylene acetabular component
Description: Patients will undergo total hip arthroplasty using a cemented acetabular component diffused with Vitamin-E

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard polyethylene acetabular component
Description: Patients will undergo total hip arthroplasty using a standard cemented acetabular component
Study: NCT00379392

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Imagery only
Description: Listening to an audio tape to enhance mental imagery of functional activities of the affected upper extremity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mental Imagery and Constraint induced therapy
Description: Listening to an audio tape to enhance mental imagery AND participation in constraint induced therapy
Study: NCT04004481

Intervention type: DRUG
Intervention: Postoperative analgesia using tramadol
Description: Tramadol 100 mg will be given to the patients in the postoperative period.
Study: NCT03975933

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test at Baseline
Description: Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test at Baseline
Description: Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test at Baseline
Description: Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Free pregnancy test for the future use
Description: We will provide a free pregnancy test in for the future use.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Free pregnancy test for the future use
Description: We will provide a free pregnancy test in for the future use.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test for the future use with randomzied price
Description: We will provide an opportunity to buy a pregnancy test for the future use with randomized price.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test for the future use with randomzied price
Description: We will provide an opportunity to buy a pregnancy test for the future use with randomized price.
Study: NCT01473264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human CC10 (rhCC10)
Description: 5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human CC10 (rhCC10)
Description: 1.5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Half normal saline solution; single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
Study: NCT03329339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 L PEG with ascorbic acid with prepackaged, low residue diet
Description: Participants who were allocated to the 2 L PEG with ascorbic acid (PEGA) group took 250 ml of PEG with ascorbic acid at 15-min intervals, completing 1 L of the PEG with ascorbic acid protocol at 8:00 PM on the day prior to the procedure. The remaining 1 L of the PEG with ascorbic acid solution was administered in the same manner at 6:00 AM on the day of the procedure. Participants assigned to the 1 L PEG with ascorbic acid with PLD (PLD) group consumed a prepackaged, low residue diet (ZeroCol, Korea Medical Food Inc., Seoul, Korea) which consisted of a breakfast, lunch and dinner, the day prior to colonoscopy. The Participants took 1 L PEG with ascorbic acid solution at 6:00 AM on the day of the colonoscopy in the same way as described above. All of the subjects ingested 500 mL of water for every 1 L of 1 L PEG with ascorbic acid solution consumed. The Participants completed all of the administrations at least 2 hours before the colonoscopy.
Study: NCT00408512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiazides
Description: Up to 25 mg per day
Study: NCT03728010

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrical impedance tomography. Pulmonary mechanics measurement.Arterial gas measurement. Esophageal pressure measurement
Description: After general anesthesia, patients will be ventilated with three tidal volume level (4, 6 and 8 cc / Kg / IBW), in two levels of PEEP, 6 cm2 H20, and best PEEP, the latter obtained after a recruitment maneuver and decremental titration.
Study: NCT03485235

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D&C
Description: Dilatation and curettage
Study: NCT00408512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non thiazidic treatment
Description: Amximum tolerated dosage as indicated from the label
Study: NCT00313963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Intravenous Magnesium Sulfate (100 mg/Kg, Max 2 gram/dose) 8 hourly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Intravenous Placebo (Normal Saline in equivalent amount to magnesium sulfate 100 mg/Kg, Max 2 gram/dose) 8 hourly.
Study: NCT02497586

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic resonance spectroscopy
Description: Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. It is a well-established technique in imaging brain cancers.
Study: NCT03479398

Intervention type: BEHAVIORAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT) is an evidence-based psychotherapy that treats a variety of disorders. In this study, clinicians will be enrolled who use types of CBT for anxiety disorders, depression and PTSD in their routine clinical practice. CBT is usually a 12-16 session treatment that focuses on intervening on disorders cognitively and behaviorally through the use of worksheets during session and outside of session.

Intervention type: BEHAVIORAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT) is an evidence-based psychotherapy that treats a variety of disorders. In this study, clinicians will be enrolled who use types of CBT for anxiety disorders, depression and PTSD in their routine clinical practice. CBT is usually a 12-16 session treatment that focuses on intervening on disorders cognitively and behaviorally through the use of worksheets during session and outside of session.
Study: NCT03485235

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICSI
Description: Intra Cytoplasmic Sperm Injection
Study: NCT01215773

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching to HEA 200 mg tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: High dose oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: Medium dose oral administration
Study: NCT04238819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered IV
Study: NCT00006095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT04238819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Administered subQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Administered subQ
Study: NCT03170544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 4.0 nmol/kg
Description: MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 8.0 nmol/kg
Description: MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 8.0 nmol/kg
Description: MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 8.0 nmol/kg
Description: MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 16 nmol/kg
Description: MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 16 nmol/kg
Description: MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 32 nmol/kg
Description: MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 32 nmol/kg
Description: MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 32 nmol/kg
Description: MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 64 nmol/kg
Description: MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Study: NCT00235989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta 1b (Betaseron, BAY86-5046)
Description: 250 mcg administered s.c.(subcutaneous) every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta 1b (Betaseron, BAY86-5046)
Description: 250 mcg administered s.c. every other day (for patients having received 500 mcg before)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta 1b (Betaseron, BAY86-5046)
Description: 500 mcg administered s.c. every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta 1b (Betaseron, BAY86-5046)
Description: 500 mcg administered s.c. every other day (for patients having received 250 mcg before)
Study: NCT03870152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocautery Ablation (EC)
Description: For the purposes of the trial, one round of EC treatment consists of two individual EC treatments with a post-EC bronchoscopy in between to check for a response to the 1st EC treatment. Within each round, the second EC treatment will only be administered if the post-treatment bronchoscopy confirms presence of persistent high grade disease. Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline.
Study: NCT03734471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reactor Device
Description: The Reactor is a Class II FDA medical device to facilitate the insertion of chest tubes into the thoracic cavity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tube thoracostomy
Description: Traditional chest tube placement
Study: NCT03919461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol and etodolac
Description: A perioperative combined drug regimen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01433432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80 mg DR-6MP
Description: All subjects from the original study, Protocol C2/13/DR-6MP-02, whether they received test drug for 12 weeks or Purinethol for 12 weeks, will now receive an additional 12 weeks of 80 mg DR-6MP drug to be administered as 2 x 40 mg DR-6MP test tablets, once nightly, before bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg DR-6MP
Description: All subjects from the original study, Protocol C2/13/DR-6MP-02, whether they received test drug for 12 weeks or Purinethol for 12 weeks, will now receive an additional 12 weeks of 80 mg DR-6MP drug to be administered as 2 x 40 mg DR-6MP test tablets, once nightly, before bedtime.